VST Industries, India’s third-largest cigarette player with an 8% market share, still sells more Charminars than some FMCG startups sell D2C protein bars. It’s debt-free, dividend-happy (payout ~76%), and backed by British American Tobacco (32% stake). But the stock is down ~38% YoY, proving once again that even in India, not every “smoking business” guarantees a hot portfolio.
2. Introduction
VST Industries is like that underrated side actor in Bollywood—always present, always reliable, never stealing the show. While ITC grabs headlines with hotels, FMCG and mega-cap valuation debates, VST quietly sells ~8 billion sticks a year.
The irony? Cigarette volumes are shrinking in India overall, yet VST managed a 21% revenue growth from FY22–24. Not because people smoked more, but because tobacco shortages abroad made their leaf exports lucrative. Translation: less lung damage at home, more nicotine exports abroad.
But the margins? Fell from 35% to 25% as the unmanufactured tobacco segment (31% of sales) doesn’t cough up the same profits as cigarettes. Add a CEO resignation in late 2024, shifting plants from Hyderabad to Toopran, and property monetisation plans, and you’ve got a mid-cap FMCG drama playing out in slow motion.
3. Business Model – WTF Do They Even Do?
Cigarettes (69% sales): Brands like Charminar, Charms, Total, Special, Moments. Recently launched Editions Trio to chase urban smokers. Volumes fell 4% over 2 years, but ASPs cushioned revenues.
Unmanufactured Tobacco (31%): Basically selling nicotine-rich leaves to exporters. This segment saved revenues in FY24 but crushed margins.
Exports (15% of revenue): Rising contribution thanks to global tobacco shortage.
Distribution: 835 wholesale dealers, 11 lakh retail outlets = more shops than Swiggy delivery boys.
Manufacturing: Two plants in Telangana; one old plant (Azamabad) being monetised for real estate value.
Question: Would you buy into a company whose topline depends on how stressed teenagers in West Bengal feel?
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹298 Cr
₹321 Cr
₹349 Cr
-7.3%
-14.6%
EBITDA
₹77 Cr
₹73 Cr
₹70 Cr
+5.5%
+10.0%
PAT
₹56.1 Cr
₹54 Cr
₹53 Cr
+3.9%
+5.8%
EPS (₹)
3.30
3.15
3.12
+4.8%
+5.8%
Commentary: Sales down, profits up = pricing power. Smokers may complain, but they still pay. Classic sin-stock economics.
5. Valuation Discussion – Fair Value Range Only
P/E Method: EPS (TTM ₹17.2) × 18–25 = ₹310 – ₹430
EV/EBITDA: FY25 EBITDA ~₹282 Cr × 12–15 = ₹3,380 – ₹4,230 Cr → Value per share ₹200 – ₹255
DCF: Assume PAT ₹280 Cr, growth 3% (tobacco is no SaaS), cost of equity 13% → ₹270 – ₹320
📌 Fair Value Range: ₹200 – ₹330 (Current CMP ₹267 sits neatly in this band; stock is “fair but not fancy.”)
